Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon


teen suicide icon

SADAG has over 160 free Support Groups. To find out more about joining or starting a Support Group click here.


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue 6

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

“The under treatment of anxiety and depression is a health care crisis of major proportion,” says Mary Guardino, Chairman of GAMIAN (The Global Alliance of Mental Illness Advocacy Networks). “These illnesses severely impair not only the lives of the individuals with the symptoms but their families as well. It is absolutely essential that we address this very serious problem urgently.”

Founded in 1997, GAMIAN unites worldwide mental health advocacy associations including the South African Depression and Anxiety Support Group, in a global effort to dispel stigmas associated with mental illness, create awareness of treatment options and to further research in key areas such as depression and anxiety. Membership is open to mental illness advocacy associations, healthcare professionals, representatives of government agencies, consumers and other concerned individuals who are committed to the mission and goals of GAMIAN.

The World Health Organisation (WHO) reports that in the next century, the major causes of disability adjusted life years (DALY) in the economically developed countries will be the neuropsychiatric disorders. In 1990, the cost of anxiety and depression in the United States was more than $90 billion, with 75% of that cost due to absenteeism and reduced productivity in the work force as well as suicides.

Conducted via mail questionnaire to patient advocacy groups in Argentina, Austria, Belgium, Great Britain, France, Italy, South Africa, Sweden, Switzerland and the US, this first-of-its-kind survey was designed to determine the experiences of people seeking treatment for depression, anxiety and other common psychiatric disorders. Although response rates differed substantially between countries – from a low of 17.5% in France to a high of 84% in the US – the results were surprisingly similar with respect to patients’ experiences in seeking and sustaining treatment.

South African patients comprised over 400 of the respondents out of the total 3500 patients from 10 different countries who participated in the international survey by GAMIAN.

The survey was funded by an unrestricted educational grant from Bristol-Myers Squibb Company, the manufacturer of Nefazadone, an antidepressant, and Busiprone, an anxiolytic.

Despite the explosion of new therapies and greater public attention to depression and other psychiatric disorders, the vast majority of people worldwide still delay seeking initial treatment for a number of years, according to the results. Almost 35% of sufferers world-wide are only properly diagnosed after consultation with four or more doctors, with many waiting for up to four years to seek treatment for their conditions.

Other very significant information from the South African respondents indicated that sexual side-effects to medication are particularly common in South Africa, and are a major factor influencing treatment drop-out. A startling 81% of respondents reported sex performance problems as a major side effect of medication, compared to the global average of only 45.2%. Loss of sex drive recorded similar responses, with South Africa scoring the highest for decreased sex drive and impaired sexual performance side-effect profiles. Other major side-effects most commonly reported by South Africans included sleep disturbances and irritability.

The survey results showed that treatment with only pharmacotherapy is associated with fewer dropouts that treatment based exclusively on talk therapy. However, treatment modalities that combine medication and talk therapy produce the lowest drop-out rates. Dr. Kessler indicates that interactions between doctors and patients can help reduce the adverse impact of side effects on dropout. He emphasised that open communication between physician and patient regarding the success of therapy and the response rate of treatment is crucial to ensure that patient expectations of improvement are realistic. He also explained the importance of a careful evaluation of medication to minimise or avoid side effects.

Local expert Dr. Annemarie Potgieter believes that further research into side-effect profiles is necessary. “Researchers need to specifically focus on developing medication with fewer side effects and a shorter treatment duration than provided by medication currently available”, says Dr. Potgieter. In terms of the need to provide further education about mental illness, destigmatisation of the diseases forms a major component of the motivation behind intensive education programmes conducted by the Depression & Anxiety Support Group. According to Kevin Bolon, a Johannesburg Psychologist, “South African medical professionals need to be informed about being more understanding and knowledgeable when dealing with mental illness”. He further believes that the label “neurotic” is attached to patients far too easily. However, the results of the study should encourage all those who suffer from or work to treat depression, to work together in order to ultimately overcome these diseases. Charl Els, prominent Bloemfontein Psychiatrist, echoes this sentiment and believes that the high regard for medication indicated by South African patients in the survey to be a very positive sign.


Our Sponsors

Our Partners